Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alireza Nateghi-Baygi"'
Autor:
Alireza Ramandi, Jacob George, Shahin Merat, Elham Jafari, Maryam Sharafkhah, Amir Reza Radmard, Alireza Nateghi Baygi, Alireza Delavari, Zahra Mohammadi, Hossein Poustchi, Reza Malekzadeh
Publikováno v:
Hepatology International.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f2582f882ee498b8eb5b49aa6670ffd
https://doi.org/10.1007/s12072-023-10542-9
https://doi.org/10.1007/s12072-023-10542-9
Autor:
Shahin Merat, Elham Jafari, Amir Reza Radmard, Masoud Khoshnia, Maryam Sharafkhah, Alireza Nateghi Baygi, Tom Marshall, Abolfazl Shiravi Khuzani, Kar Keung Cheng, Hossein Poustchi, Reza Malekzadeh
Publikováno v:
European Heart Journal. 43:2023-2033
Aims Individuals with non-alcoholic steatohepatitis or elevated liver enzymes have increased cardiovascular mortality but are often excluded from prevention trials. We investigated the effectiveness of fixed-dose combination therapy for the preventio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::835399dcc574f88ea333b51609ee66d2
https://doi.org/10.1093/eurheartj/ehab919
https://doi.org/10.1093/eurheartj/ehab919
Autor:
Atefeh Bonyadi, Fariborz Mansour-Ghanaei, Farhang Babamahmoodi, Esmat Radmanesh, Hadiseh Hosamirudsari, Javad Khodadadi, Sara Sayar, Zeinab Mehrabi, Amir Reza Bahadori, Shahin Merat, Minoo Moghimi, Gholamali Eslami, Hashem Mousavi, Lotfollah Davoodi, Mona Ebrahimzadeh, Farahnaz Joukar, Amir Anushiravani, Ali Ali Asgari, Ali Reza Davoudi Badabi, Elham Barahimi, Saeed Jelvay, Zahra Poormontaseri, Aida Zeinali, Nasim Khajavirad, Minoosh Shabani, Hamideh Abbaspour Kasgari, Zohreh Azarkar, Rohollah Moslemi, Ahmad Hormati, Azadeh Ebrahimzadeh, Hani Esmaeilian, Shokrollah Salmanzadeh, Elham Akbarpour, Lili Rezaie Keikhaie, Kaitlyn McCann, Amir Mohammad Shabani, Abdolali Tousi, Mohammad Abdollahi, Sara Mobarak, Mohammadreza Naghipour, Hadi Mirzaei, Mohammadreza Salehi, Shervin Shokouhi, Bryony Simmons, Morteza Mobarak, Helia Nateghi Baygi, Jacob Levi, Mehdi Hassaniazad, Andrew Hill, Zahra Arizavi, Nasrollah Hasooni Bahrini, Seyed Ali Dehghan Manshadi, Fatemeh Dehghani, Hannah Wentzel, Hossein Pourmasoomi, Masoome Noori Jangi, Shoeleh Yaghoubi, Alireza Nateghi Baygi, Mehdi Salasi, Farnaz Zolfaghari, Sara Yeganeh, Elmira Azimi, Jalal Karimi, Hafez Fakheri, Mahdi Afshari, Tofigh Yaghubi Kalurazi, Anahita Sadeghi, Farshid Abedi, Sajedeh Mousaviasl, Zahra Nekoukar, Dorsa Merat, Masood Ziaee
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background: The combination of sofosbuvir (SOF) and daclatasvir (DCV) has shown preliminary efficacy for patients with COVID-19 in five open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir and da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f69baf1a0987326edb8a47d694d9afe2
https://doi.org/10.1093/jac/dkab433
https://doi.org/10.1093/jac/dkab433
Autor:
Babak Sayad, Ahmad Hormati, Andrew Hill, Maryam Latifnia, Mohammad Minakari, Alireza Bakhshipour, Babak Fattahi, Reza Malekzadeh, Fereidoun Rahmani-Samani, Farshad Sheikhesmaeili, Zahra Abna, Afsaneh Sharifian, Seyed-Mohammad Valizadeh-Toosi, Zeinab Malekzadeh, Dorsa Merat, Seyedhamid Moosavy, Fariborz Mansour-Ghanaei, Masood Ziaee, Layli Eslami, Eskandar Hajiani, Iradj Maleki, Ladan Goshayeshi, Masoudreza Sohrabi, Mojtaba Fattahi-Abdizadeh, Shahnaz Sali, Shahin Merat, Mohammad Reza Fattahi, Amir Ali Sohrabpour, Abdolsamad Gharavi, Elahe Shayesteh, Mohammad-Hossein Somi, Fatemeh Roozbeh, Amir-Houshang Sharifi, Abazar Parsi, Helia Nateghi-Baygi, Mohammad Ghezlou, Jalal Karimi, Azita Ganji, Raika Jamali, Hossein Poustchi, Hamid Kalantari, Alireza Norouzi, Alireza Janbakhsh, Saba Fakhrieh-Asl, Hossein Sardarian, Behrooz Afshar, Masoomeh Sofian, Lida Ahmadi, Alireza Nateghi-Baygi, M J Zahedi, Ali-Akbar Shayesteh, Nadieh Baniasadi, Taghi Amiriani, Hafez Fakheri, Adel F Allah Ghajary, Marjan Mokhtare, Mohammad Reza Ghadir, Shahram Agah
Publikováno v:
Clinical Infectious Diseases. 73:172-172
BACKGROUND The combination of sofosbuvir and daclatasvir is a potent, pangenotypic regimen suitable for mass-scale hepatitis C treatment, especially in resource-limited countries where newer, expensive combinations are not available. This combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f29cc647284cf0ccee298907af1c2950
https://doi.org/10.1093/cid/ciaa1768
https://doi.org/10.1093/cid/ciaa1768
Autor:
Babak Fattahi, Arghavan Haj-Sheykholeslami, Shahin Merat, Hossein Poustchi, Reza Malekzadeh, Alireza Nateghi-Baygi, Seyed Moayed Alavian, Amir Houshang Sharifi
Publikováno v:
Hepatitis Monthly. 17
Background: The combination of sofosbuvir and daclatasvir can be used to treat all genotypes of hepatitis C. Current guidelines for treating hepatitis C cirrhosis do not clarify weather 12 weeks or 24 weeks of treatment is appropriate. Objectives: In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26d07de5964cc69121091098dc1a3068
https://doi.org/10.5812/hepatmon.44564
https://doi.org/10.5812/hepatmon.44564
Autor:
Esmaeil Biazar, Aliasghar Behnamghader, Alireza Nateghi Baygi, Mehdi Rahimi, Hamid Mobedi, Houri Mivehchi
Publikováno v:
Letters in Drug Design & Discovery. 9:213-217
The purpose of this research was to study the effect of zeolite powder, with particles size range between 53 and 1180 μm, on the stability and release of vitamins A, D3 and E. Zeolite type, chemical and morphological features were studied using SEM
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fab4d3b3e7d1dd0593b55755da36a2b
https://doi.org/10.2174/157018012799079833
https://doi.org/10.2174/157018012799079833